20 (AIDX) Total Non-Current Liabilities (2024 - 2026)

20 (AIDX) posted Total Non-Current Liabilities of $466177.0 for Q1 2026, down 72.47% on a QoQ basis from $1.7 million in Q4 2025.

20 (AIDX) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends

20's Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $466177.0 for Q1 2026.

Quarterly Total Non-Current Liabilities changed N/A year-over-year to $466177.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $466177.0 (changed N/A YoY) and the FY2025 annual result came in at $1.7 million, up 133.95% from the prior year.
Total Non-Current Liabilities was $466177.0 for Q1 2026 at 20, down from $1.7 million in the prior quarter.
Across five years, Total Non-Current Liabilities topped out at $1.7 million in Q4 2025 and bottomed at $466177.0 in Q1 2026.
A 3-year average of $961155.3 and a median of $723848.0 in 2024 frame the typical range for Total Non-Current Liabilities.
Peak annual rise in Total Non-Current Liabilities reached 133.95% in 2025, while the deepest fall reached 133.95% in 2025.
20's Total Non-Current Liabilities stood at $723848.0 in 2024, then surged by 133.95% to $1.7 million in 2025, then tumbled by 72.47% to $466177.0 in 2026.
Business Quant data shows AIDX's Total Non-Current Liabilities at $466177.0 in Q1 2026, $1.7 million in Q4 2025, and $723848.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	20.94 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	41.44 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	41.88 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	2.64 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	3.53 Bn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	9.85 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	24.21 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	3.57 Bn
10	20	3.91 Mn	-313,912.28	62,884.00	466,177.00

Download Data